Targeting histone acetyltransferases (HATs) like EP300 and CREBBP, which catalyze H3K27ac, has emerged as a therapeutic strategy to modulate transcriptional programs implicated in CRC progression (266, 267). This evidence concerns the gene CREBBP and colorectal carcinoma.